Analysts Set OptimizeRx Co. (NASDAQ:OPRX) Target Price at $15.86

OptimizeRx Co. (NASDAQ:OPRX) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.86.

OPRX has been the topic of several research reports. JMP Securities reiterated a “market outperform” rating and issued a $15.00 price target on shares of OptimizeRx in a report on Tuesday. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 price target on shares of OptimizeRx in a research note on Monday, April 1st. Barclays assumed coverage on OptimizeRx in a report on Wednesday, January 3rd. They issued an “equal weight” rating and a $15.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price objective on shares of OptimizeRx in a research note on Monday, April 1st.

OptimizeRx Trading Down 1.9 %

NASDAQ:OPRX opened at $9.35 on Friday. The firm has a fifty day simple moving average of $13.36 and a 200-day simple moving average of $11.95. OptimizeRx has a 12 month low of $6.92 and a 12 month high of $16.65.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPRX. Kennedy Capital Management LLC acquired a new position in OptimizeRx during the third quarter worth $4,323,000. Jacob Asset Management of New York LLC raised its holdings in OptimizeRx by 30.1% in the third quarter. Jacob Asset Management of New York LLC now owns 370,330 shares of the company’s stock valued at $2,881,000 after acquiring an additional 85,720 shares in the last quarter. Quadrature Capital Ltd purchased a new position in OptimizeRx in the third quarter worth approximately $162,000. Tower Research Capital LLC TRC grew its holdings in OptimizeRx by 407.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,765 shares of the company’s stock worth $97,000 after acquiring an additional 5,432 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of OptimizeRx during the third quarter worth $49,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.